Cargando…
A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity
BACKGROUND: Nontuberculous mycobacteria (NTM) lung diseases are increasingly recognized as chronic opportunistic infections, occurring in individuals with a wide variety of underlying conditions. In the absence of systemic immunodeficiency, decision of NTM lung disease treatment must relies on a car...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295085/ https://www.ncbi.nlm.nih.gov/pubmed/30547753 http://dx.doi.org/10.1186/s12879-018-3559-x |
_version_ | 1783380841279258624 |
---|---|
author | Provoost, Judith Valour, Florent Gamondes, Delphine Roux, Sandrine Freymond, Nathalie Perrot, Emilie Souquet, Pierre-Jean Kiakouama-Maleka, Lize Chidiac, Christian Lina, Gérard Dumitrescu, Oana Sénéchal, Agathe Ader, Florence |
author_facet | Provoost, Judith Valour, Florent Gamondes, Delphine Roux, Sandrine Freymond, Nathalie Perrot, Emilie Souquet, Pierre-Jean Kiakouama-Maleka, Lize Chidiac, Christian Lina, Gérard Dumitrescu, Oana Sénéchal, Agathe Ader, Florence |
author_sort | Provoost, Judith |
collection | PubMed |
description | BACKGROUND: Nontuberculous mycobacteria (NTM) lung diseases are increasingly recognized as chronic opportunistic infections, occurring in individuals with a wide variety of underlying conditions. In the absence of systemic immunodeficiency, decision of NTM lung disease treatment must relies on a careful risk/benefit assessment, given the requirement of long-term administration of multidrug therapies supported by limited evidence. The primary objective was to identify the factors associated with anti-NTM treatment initiation. Clinical and radiological outcome upon treatment were studied. METHODS: This retrospective, single center study (2013–2016, 45 months) addressed the criteria supporting treatment decision among adults with NTM lung disease without systemic immunodeficiency at our institution, with the assigned goal to harmonize the practice. All patients matched the current international definitions of NTM lung disease according to the American Thoracic Society criteria. Factors associated with anti-NTM treatment were investigated by conditional logistic regression. Clinical and radiological outcomes of treated and untreated NTM-disease cases were examined. Mortality rate was assessed. An expert radiologist conducted a blinded computed tomography (CT)-scan review of the treated and untreated patients. RESULTS: Among 51 cases of NTM lung diseases, 25 (49%) received anti-NTM treatment. In univariate analysis, a body mass index (BMI) < 18 kg/m(2) (odds ratio (OR), 4.2 [95% confidence interval (CI) 1.2–15.2]; p = 0.042), hemoptysis (OR, 11.8 [95% CI 1.35–12.9]; p = 0.026), excavation(s) (OR, 4.8 [95% CI 1.4–16.4], p = 0.012), prior anti-NTM treatment (OR, 5.65 [95% CI 1.06–29.9]; p = 0.042), Aspergillus spp. co-infection (OR, 6.3 [95% CI 1.8–22.2]; p = 0.004) were associated with treatment initiation. In multivariate analysis, Aspergillus spp. co-infection was the only independent determinant of treatment initiation (OR, 5.3 [95% CI 1.1–25.4]; p = 0.036). Twenty-one (81%) patients received ≥3 anti-NTM drugs. Median treatment duration and follow-up were 36.3 (interquartile range [IQR], 13.1–64.4) weeks and 17.1 (IQR, 8.7–27.1) months, respectively. Regarding radiological outcome, 85 CT-scans were reviewed, showing similar rates of regression or stabilization in treated and untreated patients. Overall mortality rate was not different in treated and untreated patients. CONCLUSION: The most relevant variable associated with anti-NTM treatment initiation was Aspergillus spp. co-infection. Radiological regression or stabilization of pulmonary lesions was not different between the treated and untreated patients. |
format | Online Article Text |
id | pubmed-6295085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62950852018-12-18 A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity Provoost, Judith Valour, Florent Gamondes, Delphine Roux, Sandrine Freymond, Nathalie Perrot, Emilie Souquet, Pierre-Jean Kiakouama-Maleka, Lize Chidiac, Christian Lina, Gérard Dumitrescu, Oana Sénéchal, Agathe Ader, Florence BMC Infect Dis Research Article BACKGROUND: Nontuberculous mycobacteria (NTM) lung diseases are increasingly recognized as chronic opportunistic infections, occurring in individuals with a wide variety of underlying conditions. In the absence of systemic immunodeficiency, decision of NTM lung disease treatment must relies on a careful risk/benefit assessment, given the requirement of long-term administration of multidrug therapies supported by limited evidence. The primary objective was to identify the factors associated with anti-NTM treatment initiation. Clinical and radiological outcome upon treatment were studied. METHODS: This retrospective, single center study (2013–2016, 45 months) addressed the criteria supporting treatment decision among adults with NTM lung disease without systemic immunodeficiency at our institution, with the assigned goal to harmonize the practice. All patients matched the current international definitions of NTM lung disease according to the American Thoracic Society criteria. Factors associated with anti-NTM treatment were investigated by conditional logistic regression. Clinical and radiological outcomes of treated and untreated NTM-disease cases were examined. Mortality rate was assessed. An expert radiologist conducted a blinded computed tomography (CT)-scan review of the treated and untreated patients. RESULTS: Among 51 cases of NTM lung diseases, 25 (49%) received anti-NTM treatment. In univariate analysis, a body mass index (BMI) < 18 kg/m(2) (odds ratio (OR), 4.2 [95% confidence interval (CI) 1.2–15.2]; p = 0.042), hemoptysis (OR, 11.8 [95% CI 1.35–12.9]; p = 0.026), excavation(s) (OR, 4.8 [95% CI 1.4–16.4], p = 0.012), prior anti-NTM treatment (OR, 5.65 [95% CI 1.06–29.9]; p = 0.042), Aspergillus spp. co-infection (OR, 6.3 [95% CI 1.8–22.2]; p = 0.004) were associated with treatment initiation. In multivariate analysis, Aspergillus spp. co-infection was the only independent determinant of treatment initiation (OR, 5.3 [95% CI 1.1–25.4]; p = 0.036). Twenty-one (81%) patients received ≥3 anti-NTM drugs. Median treatment duration and follow-up were 36.3 (interquartile range [IQR], 13.1–64.4) weeks and 17.1 (IQR, 8.7–27.1) months, respectively. Regarding radiological outcome, 85 CT-scans were reviewed, showing similar rates of regression or stabilization in treated and untreated patients. Overall mortality rate was not different in treated and untreated patients. CONCLUSION: The most relevant variable associated with anti-NTM treatment initiation was Aspergillus spp. co-infection. Radiological regression or stabilization of pulmonary lesions was not different between the treated and untreated patients. BioMed Central 2018-12-14 /pmc/articles/PMC6295085/ /pubmed/30547753 http://dx.doi.org/10.1186/s12879-018-3559-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Provoost, Judith Valour, Florent Gamondes, Delphine Roux, Sandrine Freymond, Nathalie Perrot, Emilie Souquet, Pierre-Jean Kiakouama-Maleka, Lize Chidiac, Christian Lina, Gérard Dumitrescu, Oana Sénéchal, Agathe Ader, Florence A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title | A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title_full | A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title_fullStr | A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title_full_unstemmed | A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title_short | A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
title_sort | retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295085/ https://www.ncbi.nlm.nih.gov/pubmed/30547753 http://dx.doi.org/10.1186/s12879-018-3559-x |
work_keys_str_mv | AT provoostjudith aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT valourflorent aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT gamondesdelphine aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT rouxsandrine aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT freymondnathalie aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT perrotemilie aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT souquetpierrejean aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT kiakouamamalekalize aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT chidiacchristian aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT linagerard aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT dumitrescuoana aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT senechalagathe aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT aderflorence aretrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT provoostjudith retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT valourflorent retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT gamondesdelphine retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT rouxsandrine retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT freymondnathalie retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT perrotemilie retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT souquetpierrejean retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT kiakouamamalekalize retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT chidiacchristian retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT linagerard retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT dumitrescuoana retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT senechalagathe retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity AT aderflorence retrospectivestudyoffactorsassociatedwithtreatmentdecisionfornontuberculousmycobacteriallungdiseaseinadultswithoutalteredsystemicimmunity |